Geron Co. (NASDAQ:GERN - Free Report) - Leerink Partnrs issued their Q3 2024 EPS estimates for shares of Geron in a research report issued to clients and investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid anticipates that the biopharmaceutical company will post earnings per share of ($0.09) for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Geron's current full-year earnings is ($0.35) per share. Leerink Partnrs also issued estimates for Geron's Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.07 EPS, FY2025 earnings at $0.12 EPS and FY2026 earnings at $0.39 EPS.
Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $0.88 million during the quarter, compared to analyst estimates of $0.34 million. Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. The company's revenue was up 2941.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.09) earnings per share.
A number of other equities research analysts have also weighed in on GERN. Needham & Company LLC restated a "buy" rating and issued a $6.00 price objective on shares of Geron in a report on Friday, August 9th. Wedbush reissued an "outperform" rating and issued a $8.00 price target on shares of Geron in a research note on Thursday, August 8th. StockNews.com raised Geron to a "sell" rating in a research note on Monday, August 5th. Barclays assumed coverage on Geron in a research note on Monday, June 10th. They issued an "overweight" rating and a $9.00 target price for the company. Finally, Stifel Nicolaus increased their target price on Geron from $6.00 to $7.00 and gave the company a "buy" rating in a report on Monday, June 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Geron has an average rating of "Moderate Buy" and an average price target of $7.06.
Get Our Latest Stock Analysis on Geron
Geron Price Performance
NASDAQ:GERN traded up $0.05 during mid-day trading on Wednesday, reaching $4.39. The stock had a trading volume of 5,136,095 shares, compared to its average volume of 10,908,009. The stock has a market capitalization of $2.60 billion, a P/E ratio of -12.54 and a beta of 0.50. The firm has a 50 day moving average price of $4.57 and a two-hundred day moving average price of $3.91. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61. Geron has a one year low of $1.64 and a one year high of $5.34.
Insider Activity at Geron
In other Geron news, COO Andrew J. Grethlein sold 674,348 shares of the stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $4.56, for a total value of $3,075,026.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.10% of the stock is owned by company insiders.
Institutional Investors Weigh In On Geron
Institutional investors and hedge funds have recently modified their holdings of the stock. National Bank of Canada FI increased its position in shares of Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 6,000 shares during the period. Crewe Advisors LLC raised its position in shares of Geron by 870.0% in the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 8,700 shares in the last quarter. Kingsview Wealth Management LLC purchased a new position in shares of Geron in the 1st quarter valued at approximately $34,000. American Trust bought a new stake in shares of Geron during the first quarter valued at approximately $38,000. Finally, CIBC Asset Management Inc boosted its position in shares of Geron by 32.7% during the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company's stock valued at $65,000 after purchasing an additional 3,805 shares in the last quarter. 73.71% of the stock is owned by hedge funds and other institutional investors.
About Geron
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Further Reading
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
